EcoDrugPlus

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSLBEG00000014485
Gene Symbol: HTR1B
1 Cross references
183 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSLBEG00000025561
Gene Symbol: HTR1E
4 Cross references
148 Possible Orthologues:

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSLBEG00000027362
Gene Symbol: HTR1F
4 Cross references
142 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSLBEG00000022509
Gene Symbol: HTR2A
3 Cross references
216 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSLBEG00000024759
Gene Symbol: HTR2B
3 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine Receptor 2c-Like

Ensembl ID : ENSLBEG00000023033
Gene Symbol: LOC109995581
3 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSLBEG00000009489
Gene Symbol: HTR3A
3 Cross references
203 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSLBEG00000009440
Gene Symbol: HTR3B
2 Cross references
174 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSLBEG00000012464
Gene Symbol: HTR4
3 Cross references
198 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSLBEG00000008943
Gene Symbol: HTR5A
3 Cross references
209 Possible Orthologues:

5-Hydroxytryptamine Receptor 6

Ensembl ID : ENSLBEG00000015013
Gene Symbol: HTR6
1 Cross references
114 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSLBEG00000002622
Gene Symbol: HTR7
3 Cross references
196 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).